Collegium Pharmaceutical

Collegium Pharmaceutical is a specialty pharmaceutical company that develops and commercializes products aimed at addressing pain management while mitigating the risks of prescription drug abuse. The company utilizes its proprietary DETERx platform technology, which ensures that its formulations maintain extended-release and safety profiles even when subjected to common methods of misuse such as chewing or crushing. Collegium's product lineup includes Xtampza ER, an abuse-deterrent, extended-release oral formulation of oxycodone, and Nucynta products, which consist of both extended-release and immediate-release formulations of tapentadol. These offerings are designed to manage chronic pain and provide effective treatment solutions while incorporating tamper-resistant features to combat non-medical use. Headquartered in Stoughton, Massachusetts, Collegium Pharmaceutical was incorporated in 2002 and has focused on building a portfolio of innovative products that align with evolving patient needs and regulatory standards.

Joseph Ciaffoni

President and CEO

2 past transactions

Ironshore Pharmaceuticals

Acquisition in 2024
Ironshore Pharmaceuticals Inc. is a pharmaceutical company whose mission is to develop and commercialize first-in-class treatment options to improve the lives of patients and caregivers.

BioDelivery Sciences

Acquisition in 2022
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for pain management and addiction medicine. Headquartered in Raleigh, North Carolina, the company utilizes its proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology, which features a small erodible polymer film designed for application to the buccal mucosa. Its product offerings include BELBUCA, a buprenorphine buccal film for chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for opioid dependence; ONSOLIS, a fentanyl buccal soluble film for breakthrough cancer pain; and Symproic, which addresses opioid-induced constipation in adult patients with chronic non-cancer pain. Founded in 1997, BioDelivery Sciences is committed to addressing significant unmet medical needs through innovative therapeutic solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.